Physician profile
Seth E Persky
NPI 1508823600
$1,976.10
in general payments reported to CMS, 2019-2025
22 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $120 · 2021: $25.24 · 2023: $163 · 2024: $484 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $286.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $275.61 | 2019-2025 | |
| Pfizer INC. | $205.97 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $163.32 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.45 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $132.24 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Janssen Biotech, INC. | $123.33 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $102.65 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $91.43 | 2019 | |
| Lilly USA, LLC | $73.05 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $54.27 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $50.82 | 2020-2021 | |
| Ardelyx, INC. | $43.05 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $41.03 | 2023 | Ocaliva |
| Novo Nordisk INC | $30.44 | 2025 | Wegovy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $30.20 | 2019-2020 | |
| Shionogi INC | $29.33 | 2019 | |
| Allergan, INC. | $26.56 | 2019-2020 | |
| Capsovision, INC. | $18.13 | 2024 | Capsocam Plus |
| Braintree Laboratories, INC. | $18.09 | 2023 | Suflave |
| Celgene Corporation | $14.76 | 2023 | Zeposia |
| Olympus America INC. | $13.98 | 2024 | Evis X1 Video System Center |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Persky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.